Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02821793
Other study ID # IB 2015-06
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 2016
Est. completion date July 2020

Study information

Verified date September 2018
Source Institut Bergonié
Contact SOUBEYRAN Pierre-Louis, MD, PhD
Email p.soubeyran@bordeaux.unicancer.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The main objective of study is to describe the priorities of elderly patients (70 years and over) undergoing a first medical treatment for cancer, at initiation of treatment and after 3 months of treatment. The main criterion is a prioritization of 4 items per patient from a list of 8 expectations regarding the objectives of their treatment: treatment efficacy, life expectancy, autonomy, daily activities, social activities, heaviness of treatment, toxicity, economics.


Description:

For the primary endpoint assessment, this self-administered patient questionnaire will used an opinion scale (Not at all, A little, Moderately, Enough, Many) to explore the eight domains. Next to the completion of the expectations questionnaire, patients will have to order 4 of the different 8 items that they prioritized in regard of the first line treatment that has just been prescribed by their physician.

Secondary endpoint will focus on those 8 proposed expectations of patients at different periods of time since treatment initiation. Patients' priorities will be compared to physician's priorities (using the same prioritization grid) before medical treatment and after 3 months of treatment and to younger patients' priorities (18-69 years). Associations between elderly patients' characteristics (social, medical…) and their priorities will be search.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date July 2020
Est. primary completion date May 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Male or female:

1. Age = 70 years

2. Aged 18-69 years (case population)

2. ECOG / performance status 0-3 (WHO).

3. First line of medical oncology treatment (chemotherapy, targeted therapy, hormone therapy, combination):

1. Neo-adjuvant setting,

2. Adjuvant setting: previous neo-adjuvant treatment is allowed,

3. Metastatic setting: previous neo-adjuvant and/or adjuvant treatment are allowed,

4. Solid tumors (breast, colorectal, kidney, lung, prostate, sarcoma, and ovarian) and lymphoma (indolent and aggressive).

5. Life expectancy of more than 3 months.

6. Patients potentially compliant with the rules of the follow-up study.

7. Patients affiliated to a social security scheme.

8. Patients who received clear information from the investigator on the study and had not refused to participate.

Exclusion Criteria:

1. Exclusive surgery treatment.

2. Exclusive radiotherapy treatment or in combination with oncological medical treatment (concomitant radio-chemotherapy or radio-hormonotherapy).

3. Previous first line of oncological medical treatment in the same indication as the one concerned by the inclusion:

1. Neo-adjuvant setting: previous line(s) of neo-adjuvant medical treatment,

2. Adjuvant setting: previous line(s) of adjuvant medical treatment,

3. Metastatic setting: previous line(s) of metastatic medical treatment,

4. Supportive care without specific medical treatment

5. Previous or ongoing cancer under treatment at the time of inclusion.

6. Patient already included in this study

7. Patient who for psychological, psychiatric, social, family or geographical reasons could not be regularly monitored according to the criteria of the study; patient private of liberty or under guardianship.

Study Design


Intervention

Other:
Consultation, evaluation questionnaire
Consultation, evaluation questionnaire
Geriatric consultation, evaluation questionnaire
Geriatric consultation, evaluation questionnaire

Locations

Country Name City State
France Institut Bergonié Bordeaux

Sponsors (3)

Lead Sponsor Collaborator
Institut Bergonié AG2R La Mondiale, Fondation Université de Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Priorities of patients aged 70 and over and receiving first medical treatment for cancer. Main criteria is a prioritization of 4 items selected from a list of 8 expectations regarding the objectives of their treatment : efficacy , life expectancy , autonomy, daily activities , social activities, cumbersome treatment , toxicity, economics Day 0 initiation of treatment
Primary Priorities of patients aged 70 and over and receiving first medical treatment for cancer Main criteria is a prioritization of 4 items selected from a list of 8 expectations regarding the objectives of their treatment : efficacy , life expectancy , autonomy, daily activities , social activities, cumbersome treatment , toxicity, economics . 3 months after initiation of treatment
Secondary Intra- individual reproducibility of the prioritization grid regarding the initial measurement of priorities of the elderly. Day 0 initiation of treatment
Secondary Describe expectations of patients at initiation of treatment Day 0 initiation of treatment
Secondary Describe expectations of patients 3 months after initiation of treatment 3 months after initiation of treatment
Secondary Describe priorities and expectations of patients, at 6 months after initiation of treatment 6 months after initiation of treatment
Secondary Describe priorities and expectations of patients, at 12 months after initiation of treatment 12 months after initiation of treatment
Secondary Describe 3 months after initiation of treatment, the rate of stable patients in their priorities 3 months after initiation of treatment
Secondary Describe 6 months after initiation of treatment, the rate of stable patients in their priorities 6 months after initiation of treatment
Secondary Describe 12 months after initiation of treatment, the rate of stable patients in their priorities 12 months after initiation of treatment
Secondary Overall survival, according to priorities changing or not 3 months after initiation of treatment
Secondary Compare priorities of older subjects compared to younger patients or physician's priorities 3 months after initiation of treatment
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A